



**CHARITY COMMISSION  
FOR ENGLAND AND WALES**

**Trustees' Annual Report for the period**

From	Period start date			To	Period end date		
	Day	Month	Year		Day	Month	Year
	23	June	2022		22	June	2023

Charity name	Radiotherapy UK
Other names charity is known by	ACCORN Action Radiotherapy
Charity registration number	1135902

**Objectives and Activities**

	SORP reference	
Summary of the purposes of the charity as set out in its governing document	Para 1.17	<ol style="list-style-type: none"> <li><b>1. To promote, support and encourage research into radiotherapy, radiobiology and allied subjects, and the dissemination of the useful results of such research by such actions as:</b> <ol style="list-style-type: none"> <li>a. Promoting and facilitating multidisciplinary collaboration between researchers and practitioners in radiotherapy and its allied subjects</li> <li>b. Informing patients and the public about practice and research in radiotherapy and its allied subjects, and engaging patients and the public in the development of research projects</li> <li>c. Awarding grants as appropriate</li> </ol> </li> <li><b>2. To advance and benefit the practice of radiotherapy and its allied subjects to relieve sickness and preserve good health by such actions as:</b> <ol style="list-style-type: none"> <li>a. Promoting and facilitating multidisciplinary networking and sharing of expertise and best practice</li> <li>b. Promoting and encouraging the study of the science and practice of radiotherapy and its allied subjects</li> <li>c. Promoting and facilitating increased involvement of allied professions</li> <li>d. Facilitating development and dissemination of best practices in radiotherapy and its allied subjects</li> <li>e. Disseminating knowledge concerning all aspects of the science and practice of radiotherapy and its allied subjects</li> <li>f. Promoting and facilitating education and training in the research and practice of radiotherapy and its allied subjects</li> </ol> </li> </ol>

<p>Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.</p>	<p>Para 1.17 and 1.19</p>	<p><i>1. Patient information resources</i></p> <p>The Radiotherapy UK website is a trusted source of information about radiotherapy for both the radiotherapy workforce and patients. We work with patients and in collaboration with like-minded organisations to deliver accessible information resources that support patients being experts in their own care.</p> <p><i>2. Advocacy and Campaigning</i></p> <p>We work in partnership with patients, academics, workforce, industry and professional bodies to campaign for increased access to high quality radiotherapy for all in the UK and to raise awareness of how cost-effective significant solutions that radiotherapy offers could positively impact on record-breaking wait times for treatment.</p> <p>Radiotherapy UK is proud to be the charity partner of the <a href="#">Radiotherapy4Life</a> campaign and co-founder of the <a href="#">#CatchUpWithCancer</a> campaign – a patient campaign to raise awareness of the backlogs in cancer treatment and propose realistic and workable solutions. We provide analysis of data and research and media opportunities to support this work.</p> <p>Our work also has global reach through our partnership with the Global Coalition for Radiotherapy as we work to support other countries advocate for increased radiotherapy services for cancer patients.</p> <p><i>3. Workforce engagement and support</i></p> <p>We conduct an annual Workforce Survey to determine the current issues faced by front-line staff, and to provide a platform that the multi-disciplinary workforce can share their experiences, challenges and best practice.</p> <p>Our RTUK Talks series focuses on providing opportunities for the workforce to learn and engage with ideas, innovations and technologies that can support them in developing patient-centred care and practice.</p> <p>Through our Champion's Network we support an active network of radiotherapy professionals who offer frontline insights, mutual support, education and research sharing. We promote radiotherapy careers through collating open radiotherapy job listings on the Daily News and to the Radiotherapy UK website.</p> <p><i>4. General fundraising/events</i></p> <p>The charity raises funds from a variety of sources including online giving, fundraising events, corporate partnerships, donations and grants.</p> <p>The charity is developing an annual calendar of fundraising opportunity, including an annual active challenge and Christmas Appeal.</p> <p>The charity was very grateful to receive grants in this financial</p>
---	---------------------------	---

		<p>year from Astra-Zeneca, BClear and Santa Barbara Heights.</p> <p>We welcomed a new ambassador for the charity, Mrs Nighat Awan to help represent and raise awareness of the charity and lend her expertise to support with income generation.</p> <p><i>5. Radiotherapy UK secretariat to APPG</i></p> <p>We are the secretariat for the APPG for Radiotherapy, supporting the work of the Chair and the Vice-Chairs in organising events, meetings, the AGM and ensuring all APPG regulations and requirements are met. Recent publications by the APPGRT can be found <a href="#">here</a>.</p> <p><i>6. Media relations</i></p> <p>The charity campaigns have enjoyed regular press coverage including GMTV breakfast, Sky news, ITV Tonight and all major print publications. More information can be found <a href="#">here</a>.</p> <p><i>7. Communication channels</i></p> <p>Our media channels are a very strong aspect of our work and profile and we are well respected in our reach and content.</p> <ul style="list-style-type: none"> <li>(i) <b>Daily News:</b> This again has performed strongly with Daily News audience having increased from 1,808 to 1,958 this year</li> <li>(ii) <b>Twitter:</b> The Twitter feed continues to grow, and the number of followers has increased to 6,212 up from 5,665 a year ago.</li> <li>(iii) <b>Facebook:</b> The Facebook page followers have regularly increased and as of June 2022 stand at xx (2022 = 2000)</li> <li>(iv) <b>Instagram:</b> Our following sits at 2,145 compared to 1,667 in 2021.</li> <li>(v) <b>Website:</b> Since the website has been re-designed it has seen over 10,000 new visitors to the site.</li> </ul> <p><i>8. Research and Data</i></p> <p>The charity delivers analysis on publicly available data such as waiting-times for cancer treatment and produces evidence-based reports and research to better understand how radiotherapy services are currently being delivered and what needs to change to improve patient outcomes and experience.</p>
4	Para 1.18	<p>Radiotherapy UK has had regard to the guidance issued by the Charity Commission on public benefit.</p> <p>Radiotherapy UK is committed to making available to the public, information regarding radiotherapy treatment and its benefits, providing opportunities for radiotherapy professionals to share information as well as campaign for better funding for radiotherapy treatment in the UK.</p>

You may choose to include further statements where relevant about:

Contribution made by volunteers	Para 1.38	Volunteers are an important part of the charity's ability to deliver services. We rely on volunteers to support our social media engagement and through our Champions Network to promote and engage with colleagues and share front-line experiences and information to help inform our advocacy work.
---------------------------------	-----------	--

## Achievements and Performance

	SORP reference	
Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	<p>As well as the activities noted above, the charity has achieved the following this year for the benefit of patients, professionals, and the wider community:</p> <ol style="list-style-type: none"> <li>1. Public Consultation with beneficiaries</li> </ol> <p>In Summer 2022 we undertook a public consultation with our beneficiaries – patients, carers and the wider radiotherapy workforce. Over 500 patients/ carers res and 208 members of the workforce responded. The aim of this consultation was to focus on understanding the needs and viewpoints of those the charity aims to work with and support.</p> <ol style="list-style-type: none"> <li>2. Launch of Strategic Plan</li> </ol> <p>In Autumn 2022 charity launched a new Strategic Plan 2023 – 2026. It sets out the direction we are heading in and how we plan to get there. It identifies core outcomes for the charity to focus on and is informed by the views of radiotherapy patients and families, the radiotherapy workforce and key charity stakeholders. <a href="https://radiotherapy.org.uk/rtuk-consultation-response/">https://radiotherapy.org.uk/rtuk-consultation-response/</a></p> <ol style="list-style-type: none"> <li>3. Patient Engagement and Information</li> </ol> <p>From our patient and carer consultation we discovered a huge gap in the provision of consistent and quality information about radiotherapy across the entire care pathway. Half of respondents stated they had a 'moderate' knowledge of radiotherapy with nearly a third knowing 'very little or nothing' about it.</p> <p>Accurate and trusted information is crucial for patients so that they understand their radiotherapy treatment, the options available to them, and what to expect. At present, a patient's experience is entirely dependent on which centre they visit or which professional they engage with.</p> <p>To address this, we have taken initial steps this year by reviewing all existing content, creating our first Patient Engagement Group and exploring how we ensure any information we provide is high quality and trusted through appropriate accreditation.</p> <p>To support delivery of our patient engagement and information work we recruited a Comms &amp; Engagement officer with part responsibility for developing our patient resources.</p>

		<p>4. Radiotherapy Workforce Engagement</p> <p>We ran our annual Workforce Flash Survey in September 2022. Over 10% of the radiotherapy workforce responded and the findings were covered by national media including BBC Newsnight and print media.</p> <p>This year we launched our first RTUK Talks Workforce webinar series, the first three of which had 430 registrations, with a further 2 workshops planned before the end of the calendar year.</p> <p>5. Advocacy Events and Activities</p> <ul style="list-style-type: none"> <li>- Secured the support of the Daily Express to launch the first ever national newspaper campaign on radiotherapy</li> <li>- Helped secure crucial reforms to the radiotherapy tariff</li> <li>- Influenced the terms of reference of the NHS England capacity and demand review to include machine replacements,</li> <li>- 2 MP drop in Parliament events, each securing over 50 MPs engagement.</li> <li>- World Cancer Day event in Parliament with England football legend Bryan Robson OBE attended by 80 MPs. Handed in a letter calling for radiotherapy investment and a radiotherapy plan signed by the MPs to Downing Street.</li> <li>- Met with key Labour frontbench politicians to brief them on the need for investment in radiotherapy.</li> <li>- Supported Welsh parliamentarians in efforts to secure an investment of £86 million to improve radiotherapy cancer care in Wales.</li> <li>- Supported the All-Party Parliamentary Group for Radiotherapy with its inquiry into radiotherapy and subsequent Industry Summit to seek solutions.</li> </ul> <p>6. Secretariat for the APPG</p> <p>Radiotherapy UK continues to act as secretariat to the All-Party Parliamentary Group for radiotherapy (APPG-RT). The group aims to be the voice in Parliament of cancer patients, their families and of those who work within the radiotherapy field. The APPG now has 55 (up from 49 the previous year) members/officers from various political parties/House of Lords. This year saw the relaunch of the APPG-RT Manifesto.</p> <p>7. Research &amp; Data</p> <p>We developed and launched an 'International Comparisons Report' to draw attention to other comparable countries that are delivering successful radiotherapy services and show what can be achieved for patients.</p>
--	--	---


#### Additional information (optional)

You may choose to include further statements where relevant about:

Achievements against objectives set	Para 1.41	N/A
Performance of fundraising activities against objectives set	Para 1.41	N/A
Other		Corporate Partnerships The charity benefits from a number of corporate partnerships for example Varian sponsor the charity's Daily News bulletin. All these partnerships are agreed on a vendor neutral basis.

#### Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	<p>The Charity's total income for this financial year was £128,257 Total expenditure for this year was £110,107 leaving the charity with a year end net profit of £18,417.</p> <p>During 2021/2022 The Charity has managed to continue its work within its limited budget by using its contacts and generous donations in kind (resources) from Price Jones Ltd.</p> <p>The Charity is confident that there are many untapped avenues of funding available to the organisation that we will be able to avail of with the introduction of additional resources to focus on this area and the financial sustainability of the charity.</p>
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	Radiotherapy UK's policy is to provide the charity with adequate financial stability and the means for it to meet its charitable objectives. Except for such funds as the Trustees consider prudent to maintain for the purposes of management and administration of the charity for the foreseeable future, all unrestricted funds are used to the purpose of general objects of the charity. The adequacy of the reserves is reviewed annually.
Amount of reserves held	Para 1.22	£196,275 (excluding the related party loan mentioned below)
Details of fund materially in deficit	Para 1.24	The Charity has a long-term interest-free loan from related party Price Jones Ltd which is repayable at £2,500pa. The balance at June 2023 is £17,672

Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	There are no current uncertainties regarding the charity continuing as a going concern.
--	-----------	---

#### **Additional information (optional)**

You may choose to include further statements where relevant about:

The charity's principal sources of funds (including any fundraising)	Para 1.47	<p>The Charity's main source of funds for this reporting period were:</p> <ol style="list-style-type: none"> <li>1. Public Donations via JustGiving, direct donations and running for radiotherapy fundraising events (to raise awareness)</li> <li>2. Corporate donations from: Varian Medical Systems, AstraZeneca, Elekta, Brainlab and Flen Health</li> <li>3. Radiotherapy4Life donation for administrative and research analysis support.</li> </ol>
Investment policy and objectives including any social investment policy adopted	Para 1.46	We do not currently hold enough reserves to warrant an investment policy.

A description of the principal risks facing the charity	Para 1.46	<p><b>Current Challenges</b></p> <ol style="list-style-type: none"> <li>1. Matching growth of charity to meet service development needs with financial constraints</li> <li>2. Strained financial environment and COL crisis creates difficult circumstances for fundraising</li> <li>3. Ensuring patients and beneficiaries engaged with services and organisational development.</li> <li>4. Developing appropriate governance structures in line with organisational growth.</li> <li>5. Unstable political environment</li> <li>6. Continuing crisis in delivery of cancer services exacerbated by workforce strikes, over-bureaucracy, limiting leadership and minimal investment.</li> </ol>
---	-----------	--

Other		<p><b>Future initiatives</b></p> <p>The following are considered to be priorities for the coming year:</p> <ol style="list-style-type: none"> <li>1. Develop appropriate governance structures to support charity growth and employment of staff</li> <li>2. Implement strategic plan.</li> <li>3. Co-ordinate and delivery a Radiotherapy Vision 2024. This will be an informed, evidence-based document, outlining what needs to happen to achieve world-class radiotherapy in the UK by 2034. The aim of this work is to combine the knowledge of patients, specialists, radiotherapy leaders, frontline workforce, professional bodies, industry and academics to create an implementable document that will meet the needs of cancer patients now and in the future.</li> <li>4. Develop new patient information resources</li> <li>5. Develop Patient Engagement and Clinical Engagement Groups</li> <li>6. Appoint dedicated resources to generate income</li> <li>7. Develop an Income Generation Strategy and Communications Strategy.</li> <li>8. Expand our workforce engagement services</li> <li>9. Continue to campaign and advocate for increased access to high quality radiotherapy services across the UK</li> </ol>
-------	--	--

## Structure, Governance and Management

<b>Description of charity's trusts:</b>		
<b>Type of governing document (trust deed, royal charter)</b>	Para 1.25	Constitution
<b>How is the charity constituted? (e.g. unincorporated association, CIO)</b>	Para 1.25	Association
<b>Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees</b>	Para 1.25	Original Trustees were nominated and elected by the ACORRN Scientific Steering Committee. New Trustees are nominated by the same process and are elected by consensus of the Board of Trustees of Radiotherapy UK.



## Reference and Administrative details

Charity name	Radiotherapy UK (previously Action Radiotherapy)
Other name the charity uses	ACORRN
Registered charity number	1135902
Charity's principal address	4 Abbotsbury House 139 Abbotsbury Road London W14 8EN

### Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1	Professor Patricia Price	Chair		Board of Trustees
2	Dr Christy Goldsmith	Secretary		Board of Trustees
3	Ms Tanya Levine	Treasurer		Board of Trustees
4	Dr Clive Harmer	Medical Advisor		Board of Trustees
5	Professor Philip Mayles	Medical Advisor		Board of Trustees
6				

### Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	None
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	None
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	None

### Additional information (optional)

#### Names and addresses of advisers (Optional information)

Type of adviser	Name	Address

#### Name of chief executive or names of senior staff members (Optional information)

Sarah Quinlan – Charity Director
----------------------------------

### Exemptions from disclosure

Reason for non-disclosure of key personnel details

Other optional information

Declarations

The trustees declare that they have approved the trustees’ report above.		
Signed on behalf of the charity’s trustees		
Signature(s)		
Full name(s)	Professor Pat Price	
Position (e.g. Secretary, Chair, etc	Chair	
Date	12 August 2023	



CHARITY COMMISSION  
FOR ENGLAND AND WALES

Radiotherapy UK

1135902

## Receipts and payments accounts

CC16a

For the period  
from

23.06.2022

To

22.06.2023

### Section A Receipts and payments

Unrestricted  
funds

Restrict  
ed funds

Endowme  
nt funds

Total funds

Last year

to the nearest  
£

to the  
nearest £

to the  
nearest £

to the nearest £

to the nearest  
£

#### A1 Receipts

Corporate donations	74,822	0	0	74,822	102,644
Community	21,752	-	-	21,752	45,233
Trusts and foundations	32,000	-	-	32,000	25,866
		-	-	0	-
		-	-	0	-
		-	-	0	-
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total (Gross income for AR)</b>	<b>128,573</b>	<b>0</b>	<b>0</b>	<b>128,573</b>	<b>173,743</b>

#### A2 Asset and investment sales, (see table).

	-	-	-	-	
	-	-	-	-	-
<b>Sub total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

**Total receipts** **128,573** **-** **-** **128,573** **173,743**

#### A3 Payments

Advocacy & campaigning	2,387	0	0	2,387	1,872
Charity running costs	2,960	0	0	2,960	2,818
Communications	6,909	0	0	6,909	16,381
Contractors	82,042	0	0	82,042	43,852
Income generation	3,539	0	0	3,539	13,133
IT & Development	4,335	0	0	4,335	2500
Loan repayments	2,500	0	0	2,500	2500
Patient Services	500	0	0	500	
Professional fees	2,415	0	0	2,415	1179
Promotional materials	42	0	0	42	7070
Salaries	3,836	0	0	3,836	
Workforce services	391	0	0	391	
<b>Sub total</b>	<b>111,856</b>	<b>0</b>	<b>0</b>	<b>111,856</b>	<b>91,305</b>

<b>A4 Asset and investment purchases, (see table)</b>					
Laptop purchases	1,056	0	0	1,056	1,036
<b>Sub total</b>	<b>1,056</b>	<b>0</b>	<b>0</b>	<b>1,056</b>	<b>1,036</b>
<b>Total payments</b>					
	<b>112,912</b>	<b>0</b>	<b>0</b>	<b>112,912</b>	<b>92,341</b>
<b>Net of receipts/(payments)</b>	<b>15,661</b>	<b>0</b>	<b>0</b>	<b>15,661</b>	<b>81,402</b>
<b>A5 Transfers between funds</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>A6 Cash funds last year end</b>	<b>180,614</b>	<b>0</b>	<b>0</b>	<b>180,614</b>	<b>99,212</b>
<b>Cash funds this year end</b>	<b>196,275</b>	<b>0</b>	<b>0</b>	<b>196,275</b>	<b>180,614</b>

Section B Statement of assets a					
Categories	Details	Unrestrict ed funds	Restricted funds	Endowment funds	
		to nearest £	to nearest £	to nearest £	
B1 Cash funds		196,275	-	-	
		-	-	-	
		-	-	-	
	<b>Total cash funds</b>	<b>196,275</b>	<b>-</b>	<b>-</b>	
	(agree balances with receipts and payments account(s))	OK	OK	OK	
	Details	Unrestrict ed funds	Restricted funds	Endowment funds	
		to nearest £	to nearest £	to nearest £	
B2 Other monetary assets		-	-	-	
		-	-	-	
		-	-	-	
		-	-	-	
		-	-	-	
		-	-	-	
		-	-	-	
B3 Investment assets	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)	
			-	-	
			-	-	
			-	-	
			-	-	
			-	-	


**B4 Assets retained for the charity's own use**

Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-

**B5 Liabilities**

Details	Fund to which liability relates	Amount due (optional)	When due (optional)
		17,672	
		-	
		-	
		-	
		-	

Signed by one or two trustees on behalf of all the trustees

Signature	Print Name	Date of approval
	PAT PRICE	20/10/23

## **Independent Examiner's Report to the Trustees of Radiotherapy UK**

I report to the trustees on my examination of the accounts of Radiotherapy UK for the year ended 22 June 2023.

### **Responsibilities and basis of report**

As the charity trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011. ('the Act').

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

### **Independent examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. Accounting records were not kept in respect of the Trust as required by section 130 of the Act; or
2. The accounts do not accord with those records.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report to enable a proper understanding of the accounts to be reached.



Susan Redmond FCA  
DJH Mitten Clarke Manchester Limited  
Chartered Accountants  
St George's House  
56 Peter Street  
Manchester  
M2 3NQ

16 October 2023

## **RADIOTHERAPY UK**

**YEAR ENDED 22 JUNE 2022**

### **NOTES TO ACCOUNTS**

#### **Interest-free loan**

The charity received an interest-free loan from Price Jones Limited, a company in which one of the trustees Professor Patricia Price is a director and shareholder. The loan currently stands at £17,672 and is repayable at £2,500 per annum beginning 1 July 2017.

#### **Related party transactions**

During the year there was a further £2,462 (2022: £12,000) paid to Price Jones Limited. These were for general administrative costs, and costs relating to the All Party Parliamentary Group for Radiotherapy. All transactions were considered to be at arm's length.

During the year donations of £44,083 (2022:£61,680) were received from Radiotherapy4Life Limited, a company in which one of the trustees Patricia Price is a director and shareholder.